Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Polyinosinic-polycytidylic acid

Polyinosinic-polycytidylic acid (Poly (I:C) ) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I) -like receptors (RIG-I and MDA5) . Polyinosinic-polycytidylic acid can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid can directly trigger cancer cells to undergo apoptosis[1][2].

Product Specifications

CAS Number

[24939-03-5]

Product Name Alternative

Poly (I:C)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcl-2 Family; HSP; Interleukin Related; PKD; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/polyinosinic-polycytidylic-acid.html

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O[C@H]1[C@@H](O[C@H](COP(O)(O)=O)[C@H]1O)N2C3=C(C(NC=N3)=O)N=C2.O[C@H]4[C@H](N5C(N=C(N)C=C5)=O)O[C@H](COP(O)(O)=O)[C@H]4O.[x].[x]

Molecular Formula

(C10H13N4O8P) x. (C9H14N3O8P) x

Precautions

H302, H315, H319, H335

References & Citations

[1]Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413 (6857) :732-738. |[2]Matsumoto M, Kikkawa S, Kohase M, Miyake K, Seya T. Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling. Biochem Biophys Res Commun. 2002;293 (5) :1364-1369. |[3]Cheng Y, Xu F. Anticancer function of polyinosinic-polycytidylic acid [J]. Cancer biology & therapy, 2010, 10 (12) : 1219-1223.|[4]Deleidi M, Hallett P J, Koprich J B, et al. The Toll-like receptor-3 agonist polyinosinic: polycytidylic acid triggers nigrostriatal dopaminergic degeneration [J]. Journal of Neuroscience, 2010, 30 (48) : 16091-16101.|[5]Forte G, Rega A, Morello S, et al. Polyinosinic-polycytidylic acid limits tumor outgrowth in a mouse model of metastatic lung cancer [J]. The Journal of Immunology, 2012, 188 (11) : 5357-5364.|[6]Rezaee F, Meednu N, Emo J A, et al. Polyinosinic: polycytidylic acid induces protein kinase D–dependent disassembly of apical junctions and barrier dysfunction in airway epithelial cells [J]. Journal of Allergy and Clinical Immunology, 2011, 128 (6) : 1216-1224. e11.|[7]Wang P F, Fang H, Chen J, et al. Polyinosinic-polycytidylic acid has therapeutic effects against cerebral ischemia/reperfusion injury through the downregulation of TLR4 signaling via TLR3 [J]. The Journal of Immunology, 2014, 192 (10) : 4783-4794.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Bax; Bcl-2; HSP70; IL-13; IL-17

Citation 01

ACS Nano. 2025 Feb 4;19 (4) :4195-4212.|Acta Pharm Sin B. 2025 Jul 9.|Autophagy. 2024 May 18.|Biochem Biophys Res Commun. 2024 Apr 16:704:149661.|bioRxiv. 2024 Dec 8:2024.12.07.627371.|bioRxiv. 2024 September 23.|Cancer Immunol Res. 2024 Oct 1;12 (10) :1438-1451.|Cancer Med. 2023 Jul;12 (14) :15676-15690.|Cell Death Discov. 2025 Jul 25;11 (1) :345.|Cell Signal. 2025 Apr 15:132:111807.|Chem Biol Drug Des. 2023 Nov;102 (5) :1110-1120.|Chem Biol Drug Des. 2025 Nov;106 (5) :e70196.|Chem Eng J. 2021 Aug 15:418:129392.|Clin Cosmet Investig Dermatol. 2024 May 14:17:1093-1105.|Clin Transl Med. 2024 Sep;14 (9) :e70027.|Curr Issues Mol Biol. 2025 May 14;47 (5) :361.|Curr Microbiol. 2024 Aug 6;81 (9) :296.|Dev Comp Immunol. 2025 Dec:173:105527.|Dev Comp Immunol. 2025 Sep 29:172:105483.|FASEB J. 2024 Mar 31;38 (6) :e23551.|Food Front. 2025 Nov 6.|Hepatology. 2025 Nov 7.|Immunity. 2025 Aug 12:S1074-7613 (25) 00314-0.|Int Immunopharmacol. 2025 Jan 11:147:114033.|J Exp Clin Cancer Res. 2025 Feb 7;44 (1) :45.|J Extracell Vesicles. 2025 May;14 (5) :e70083.|J Innate Immun. 2025 Jul 28:1-27.|J Transl Med. 2025 Nov 10;23 (1) :1252.|J Virol. 2025 Aug 19;99 (8) :e0049825.|Mol Ther. 2025 Dec 3;33 (12) :6146-6159.|Nat Cell Biol. 2025 Apr;27 (4) :683-695.|Nat Commun. 2025 Feb 24;16 (1) :1909.|Nat Commun. 2025 Jun 3;16 (1) :5140.|Nature. 2025 Jul;643 (8072) :810-819.|Patent. US20250235423A1.|Res Sq. 2024 Nov 14.|SSRN. 2023 Apr 29.|Vet Res. 2024 Sep 27;55 (1) :115.|Vet Res. 2025 Nov 5;56 (1) :210.|Virol Sin. 2023 Jun;38 (3) :335-343.|Virol Sin. 2023 Oct;38 (5) :741-754.|World J Tradit Chin Med. 2025 Oct 28.|Adv Funct Mater. 29 August 2022.|Liver Int. 2022 Dec;42 (12) :2724-2742.|Mol Ther Oncolytics. 2022 Aug 25:26:413-428.|Phytomedicine. 2021 Apr:84:153495.|SSRN. 2021 Apr 26.

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Horse Transforming Growth Factor Beta (TGF-β) ELISA Kit
JL54888-01 48 Tests

Horse Transforming Growth Factor Beta (TGF-β) ELISA Kit

Ask
View Details
Horse Transforming Growth Factor Beta (TGF-β) ELISA Kit
JL54888-02 96 Tests

Horse Transforming Growth Factor Beta (TGF-β) ELISA Kit

Ask
View Details
Lentiviral human OXCT1 shRNA (UAS) - Lentiviral human OXCT1 shRNA (UAS, iRFP) (100)
GTR15106887 1 Vial

Lentiviral human OXCT1 shRNA (UAS) - Lentiviral human OXCT1 shRNA (UAS, iRFP) (100)

Ask
View Details
Mouse Monoclonal S100P Antibody (S100P/7373) [Janelia Fluor 635]
NBP3-20832JF635 0.1 mL

Mouse Monoclonal S100P Antibody (S100P/7373) [Janelia Fluor 635]

Ask
View Details
AAAS Antibody
MBS9609499-01 0.1 mL

AAAS Antibody

Ask
View Details
AAAS Antibody
MBS9609499-02 0.2 mL

AAAS Antibody

Ask
View Details